Message #33 From:
Stock News Bot Date: December 5, 2006 08:58:00 AM
CLRI News CORRECTING and REPLACING Clearant Sets New Record with November Sterile Implant Sales
LOS ANGELES--(BUSINESS WIRE)--The second graph, second sentence should read: 73 Clearant Process
Sterile Implants were sold xxx (sted 65 Clearant Process Sterile
Implants were sold xxx), and the third sentence should read: xxx sales
have already exceeded total third quarter sales by about 40 percent.
(sted xxx sales have already exceeded total third quarter sales by about
25 percent.)
The corrected release reads:
Clearant Sets New Record with November Sterile Implant Sales
Fourth Quarter Sales Already Greater Than That of Previous Quarter
Clearant, Inc. (OTCBB:CLRI) today announced that it sold 47 Clearant
Process® Sterile Implant cervical spinal and
soft tissue allografts directly to surgeons, hospitals and clinics in
November. Nearly doubling sales from the previous month, November
implant sales were markedly higher than during any other month since
Clearant launched its direct sales initiative in June 2006.
Clearant’s direct sales figures have steadily
increased every month since it made Clearant Process Sterile Implants
available directly to surgeons and surgery centers around the country.
73 Clearant Process Sterile Implants were sold directly during the first
two months of the fourth quarter as compared to 52 sold in all of the
third quarter. During the first two months of the fourth quarter, sales
have already exceeded total third quarter sales by about 40 percent.
“Surgeons and clinics across the country are
making patient safety their highest priority by choosing to provide
sterile implants,” said Clearant Chief
Executive Officer Alain Delongchamp. “Clearant
is on pace to sell approximately 100 implants during the current
quarter, which would represent an increase of 100 percent over third
quarter sales which was our first full quarter of operations under the
new direct distribution initiative.”
About Clearant, Inc.
Clearant, Inc. is a leader in pathogen inactivation for biological
products. Clearant has developed the patent-protected Clearant Process,
which substantially reduces all types of bacteria and viruses in
biological products while maintaining the functionality of the
underlying tissue implant or protein. The Company began to distribute
directly to surgeons, hospitals and clinics Clearant Process sterile
implants in June 2006; in addition, Clearant continues to license the
Clearant Process and provides its patented sterilization services to
tissue banks and other biological products manufacturers. Clearant also
has 10 license and service agreements with tissue banks. To date more
than 9,000 patients have been successfully implanted with Clearant
Process sterile implants supplied by one of the Company's licensed
partners. Whereas various competing sterilization methods only kill
specific types of pathogens (such as bacteria or lipid-enveloped
viruses) for specific products, the Clearant Process reduces all types
of pathogens for products across many market segments including tissue
implants, plasma proteins, recombinant products, medical devices and
blood products. Also, the Clearant Process can be applied at various
stages of product processing and/or manufacturing, including in the
final packaging. For more information, please visit www.clearant.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in
this press release are forward looking and made pursuant to the Safe
Harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements reflect numerous assumptions and
involve a variety of risks and uncertainties, many of which are beyond
the company's control, which may cause actual results to differ
materially from stated expectations. These risk factors include, among
others, limited operating history, difficulty in developing, exploiting
and protecting proprietary technologies, results of additional clinical
studies, acceptance and success of our direct distribution of
allografts, efficacy of the technology, intense competition and
substantial regulation in the biotechnology industry, and additional
risks discussed in the company's filings with the SEC, available on the
SEC web site http://www.sec.gov.
